#ESMO21 Highlights on nivolumab in pretreated thymoma & thymic carcinoma: EORTC-ETOP NIVOTHYM study

Nicolas Girard reports on key results from ESMO Congress 2021 on LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

17 Sep 2021 Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings